INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/41372

A. CLASSIFICATION OF SUBJECT MATTER				
The second of th				
IPC(7) : C12P 12/08, 21/08; A61K 39/395 US CL : 530/387.3; 435/326; 424/133.1				
According to International Patent Classification (IPC) or to be	oth national classification and IDC			
B. FIELDS SEARCHED	our nadonal classification and IPC			
Minimum documentation searched (classification system followed by classification symbols)				
U.S. : 530/387.3; 435/326; 424/133.1	wed by classification symbols)			
1.27 7 2 20, 120, 120, 424, 133.1				
Documentation searched other than minimum documentation to	o the extent that such documents are include	d in the fields searched		
Electronic data beauty and a late in the l				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
11-date dec Continuațion Sheet				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category * Citation of document, with indication, where	e appropriate, of the relevant passages	Relevant to claim No.		
X / Lu, D. Complete Inhibition of Vascular Endoth	elial Growth Factor (VEGE) Activities	1-5, and 23-42		
with a Bifunctional Diabody Directed against Bo	with a Bifunctional Diabody Directed against Both VEGF Kinase Recentors fras-like			
Tyrosine Kinase Receptor and Kinase Insert Don	nain-containing Receptor Cancer			
Research October 2001, Vol 61. pages 7002-700 7004, and Figure 1.	8, especially page 7005, Table 1, page			
, <u>s</u> -				
	pecific Diabody Directed Against Two	1-4, 24-28, 30-34, and		
Different Epitopes on Vascular Endothelial Grov Methods November 1999, Vol 230. No. 1-2, pa	with Factor Receptor 2 J. Immunol.	36-42		
170 mode 170 vermoer 1999, voi 250. No. 1-2, pa	ges 139-71, especially abstract.			
	ļ			
	1			
Further documents are listed in the continuation of Box C.	See patent family annex.			
Special categories of cited documents:	"T" later document published after the interr	ational filing date or priority		
"A" document defining the general state of the art which is not considered to be	date and not in conflict with the applicat	ion but cited to understand the		
of particular relevance	principle or theory underlying the invent	ion		
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the cla	aimed invention cannot be		
	considered novel or cannot be considered when the document is taken alone	d to involve an inventive step		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as				
specified)	"Y" document of particular relevance; the cla considered to involve an inventive step w	aimed invention cannot be		
O" document referring to an oral disclosure, use, exhibition or other means	combined with one or more other such d	ocuments, such combination		
	being obvious to a person skilled in the a	urt		
P* document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent far	nily		
Date of the actual completion of the international search	Date of mailing of the international search report 30 JUN 2003			
30 April 2003 (30.04.2003)	JUN ZI	リリブ		
Name and mailing address of the ISA/US	Authorized officer			
Commissioner of Patents and Trademarks Box PCT	[Day 12	1.		
Washington, D.C. 20231	Phuong Huynh Christina Chan			
csimile No. (703)305-3230 Telephone No. (703) 308-0196				
rm PCT/ISA/210 (second sheet) (July 1998)				

	PCT/US02/41372	
INTERNATIONAL SEARCH REPORT	FC1/0302/413/2	
MILKWATIONAL SEARCH REFURI		i i
	l l	
		•
•		
	7	
Continuation of B. FIELDS SEARCHED Item 3: MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS on STN Chimeric VEGF receptor antibody, KDR, Flt-1, Flt-4, diabody, method making		•
Chimeric VEGF receptor antibody, KDR, Flt-1, Flt-4, diabody, method making	antibodies	
·		
		}
•		
•		
•		

Form PCT/ISA/210 (second sheet) (July 1998)